This Week in Biomedical Research
Researchers in Chicago are beginning the first human trial of a stem-cell therapy. Geron scientists plan to test the safety of an experimental treatment designed to restore myelin with oligodendroctye progenitor cells. See story at the LA Times.
The Food and Drug Administration has given the go-ahead to a new drug aimed at slowing the progression of multiple sclerosis. Gilenya, manufactured by Novartis, is given in pill form, and works by slowing the entry into the brain of immune cells which can cause damage by inducing inflammation.
The transgenic mouse may finally have some competition. For the first time, scientists at the University of Southern California report the creation of knockout rats using modified embryonic stem cells. This advance has been a long time in coming, and should help researchers create new rat models for a wide range of human diseases.
Facebook connect
Association of Academic Health Centers
Your Feedback